Biotech News

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Emergent BioSolutions (EBS)Emergent BioSolutions2026-04-07 12:05 ESTCompany update

New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

Emergent BioSolutions

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Recent company news

EBSEmergent BioSolutions2026-05-28 20:01 EST

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

EBSEmergent BioSolutions2026-05-20 11:30 EST

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBSEmergent BioSolutions2026-05-18 12:59 EST

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

EBSEmergent BioSolutions2026-04-30 20:30 EST

Emergent BioSolutions Reports First Quarter 2026 Financial Results

EBSEmergent BioSolutions2026-04-30 11:55 EST

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Stock data

Close: 4.82 USD
Market cap: 423.61M USD
Exchange: NYSE
Sector: Biopharma
Location: United States